Tocqueville Asset Management L.P. Purchases New Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Tocqueville Asset Management L.P. purchased a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 170,000 shares of the company's stock, valued at approximately $2,383,000. Tocqueville Asset Management L.P. owned approximately 0.41% of SI-BONE as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. FMR LLC increased its position in shares of SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after purchasing an additional 1,198 shares in the last quarter. Mainstream Capital Management LLC purchased a new stake in SI-BONE in the 4th quarter valued at $53,000. R Squared Ltd purchased a new stake in SI-BONE in the 4th quarter valued at $73,000. Walleye Capital LLC purchased a new stake in SI-BONE in the 3rd quarter valued at $144,000. Finally, Proficio Capital Partners LLC purchased a new stake in SI-BONE in the 4th quarter valued at $155,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SIBN shares. Truist Financial restated a "buy" rating and issued a $22.00 target price (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Needham & Company LLC lifted their price objective on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $24.50.

Remove Ads

SI-BONE Stock Down 2.0 %

Shares of NASDAQ SIBN traded down $0.30 during midday trading on Friday, hitting $14.66. 633,310 shares of the company's stock were exchanged, compared to its average volume of 350,688. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16. The company has a market cap of $622.36 million, a PE ratio of -15.93 and a beta of 1.17. The firm's fifty day simple moving average is $16.62 and its 200-day simple moving average is $14.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. Research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other SI-BONE news, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the transaction, the chief financial officer now owns 189,319 shares of the company's stock, valued at $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares in the company, valued at approximately $3,097,114.60. This trade represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,311 shares of company stock valued at $130,356 over the last quarter. Company insiders own 3.90% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.